Why the Disease-First Model Is Failing You
Will fixing your heart disease make you live longer and better?
Imagine researchers announce tomorrow that they have cured cardiovascular disease. Every blocked artery, every failing valve, every irregular heartbeat is gone. How many years do you think that would add to your human lifespan?
Ten years? Twenty?
According to Dr. Nir Barzilai, one of the world’s best-known geroscientists and founding director of the Institute for Aging Research at Albert Einstein College of Medicine, the right answer is “about two years”. Speaking at the 2026 Longevity World Forum, he made his point by saying:
“If we cure cardiovascular disease, we will not gain more than 2 years; truly, we have to treat aging to achieve longevity beyond 10 years.”
Two years. For curing the leading cause of death on the planet.
That number should sink in. It’s not depressing, but it tells us something about the framework modern medicine has been operating on for the better part of a century. We’ve been fighting the wrong battle. Not incompetently. Not without results. But at the wrong level.
The Model That Made Sense But Only For a While
The disease-first model didn’t emerge from ignorance. It emerged from one of medicine’s greatest triumphs.
In the early 20th century, infectious diseases accounted for the majority of deaths. Tuberculosis, pneumonia, smallpox, and cholera were the killers. Then came vaccines, antibiotics, and public health infrastructure. Within decades, diseases that had killed millions were either eradicated or reduced to manageable threats. The logic was: identify a specific disease, understand its mechanism, develop an intervention, save lives.
It worked. Life expectancy in the United States climbed from roughly 47 years in 1900 to nearly 79 years by 2019. The disease-first model felt like an engine that just needed to keep running.
The problem is that the 20th-century victories were fundamentally different in nature from what medicine is now attempting. Defeating a bacterial infection is not the same as defeating aging. The shift from infectious to chronic disease as the dominant cause of death didn’t represent a slowing of aging. It represented “a change in what kills us” at the end of a biological process.
We added years to life. But the aging and final misery that fills those years? That continued unchanged.
The Displacement Problem
When researchers at the German Center for Neurodegenerative Diseases published a landmark systematic review in late 2025, they examined what actually kills humans throughout their lifespans. What they found challenges the very premise of single-disease medicine.
Cardiovascular disease accounts for 35 to 70 percent of deaths in older adults. Even among centenarians (people who survived to 97, 100, 106 years old), virtually none died of “old age” in some abstract sense. They died of specific, identifiable diseases. Vascular conditions. Cancer. Organ failure.
The conclusion isn’t that disease doesn’t matter. It’s that disease is the mechanism through which aging kills us, not an independent enemy standing alongside it.
Think of it this way. Aging progressively erodes the body’s homeostatic systems, the intricate checks and balances that keep your cardiovascular system, your immune function, and your metabolic regulation all working in concert. As that erosion accumulates, it creates vulnerabilities. One of those vulnerabilities eventually becomes a clinical disease.
You call it heart failure, or colorectal cancer, or Parkinson’s. Medicine treats that specific expression. But the underlying erosion continues.
Cure the heart disease in isolation, and something else fills the void because the upstream driver, aging itself, was never addressed. This is mortality displacement, and it’s the structural reason why curing one major disease yields only a marginal lifespan gain.
A 2023 scientific statement in the Journal of the American College of Cardiology put it plainly: geroscience-based therapies that target mechanisms upstream of cardiovascular disease may do far more for patients than treating the cardiovascular disease itself.
The field even has a name for this: geroscience, the study of the fundamental biological mechanisms of aging, and how targeting them might simultaneously prevent or delay the entire cluster of chronic diseases we’ve been fighting one at a time.
Two Different Ways to Measure Time
Part of why this remains hard to grasp culturally is that we conflate two very different things: chronological age and biological age.
Chronological age is simply how many years you’ve been alive. It’s fixed, universal, and tells us almost nothing useful about your health trajectory. Biological age is how well your body’s systems are actually functioning relative to that clock. It varies a lot between individuals.
Two people can both be 58 years old. One has the cardiovascular resilience, inflammatory markers, and metabolic flexibility of a 45-year-old. The other has a biological profile consistent with a 70-year-old. Standard medicine treats them identically based on their birth years. They get screening for the same diseases at the same ages, prescribing based on the same risk tables. Geroscience argues this is the wrong approach.
The FDA still does not formally recognize aging/premature aging as a disease indication or preventable condition. This regulatory stance has significantly slowed clinical research into aging-targeted therapies.
Nir Barzilai and colleagues have spent years working around this constraint, using FDA-approved drugs like metformin to build evidence that targeting aging biology has population-level effects across multiple diseases simultaneously by reducing rates of type 2 diabetes, cardiovascular disease, cognitive decline, and cancer. They tried to show that working upstream, at the biological age level, rather than at the level of any single diagnosis, results in better outcomes.
What We Got Right And What We Missed
None of this is to dismiss what modern medicine has accomplished. The nearly 90 percent decline in acute heart attack mortality over the past five decades is a great achievement of the disease-first model. Survival rates for many cancers have improved substantially. People are living longer than at any point in recorded history.
But there is a difference between living longer and aging well. In the United States today, the average person spends roughly the last 12.4 years of their life managing chronic conditions, disability, or significant health limitations. We’ve extended the lifespan. The healthspan (the years lived in good health with full function) has not kept pace.
Researchers now describe this gap as one of the most important unsolved problems in medicine. And the growing consensus among the scientists closest to the problem is that closing that gap requires a fundamental reorientation: from treating the products of aging to addressing the process of aging itself.
That reorientation is what geroscience represents.
The Question - Change Everything?
The disease-first model was never wrong, exactly. It was just incomplete. It answered the question “what is killing this person right now?” What it didn’t answer is “why is aging making this person killable?”
This new science is advancing rapidly, and if you’re over 50, it is arguably the most important scientific story you should be following now.
In Part 2, I’ll explain the new framework reshaping how the world’s top researchers think about aging.